ResMed Inc. (RMD) Stock Analysis
Is RMD a good investment?
ResMed Inc. (RMD) has a Plutrex AI rating of 70.0/100 as of November 02, 2026, indicating a Buy consensus. The stock is halal-compliant per AAOIFI standards. Key strength: Unmatched profitability in the sector: operating margin 34.82% (2.5x industry avg 14.01%), net margin 27.79% (4.5x industry avg 6.18%), ROE 26.4% (3.4x industry avg 7.81%) — all achieved with near-zero leverage (D/E 0.07 vs. industry 0.54), confirming genuine economic moat. Main concern: Structural growth lag vs. peers: forward 5-year EPS growth of 9.2% trails industry average of 12.76% by -28.0%, and revenue growth of 5.9% trails industry average of 12.64% by -53.3% — the business is a high-quality compounder but a below-average grower in its peer group, limiting multiple expansion potential.
Investment Summary
ResMed (RMD) at $229.94 is an exceptional medical device franchise trading at modestly elevated but more reasonable valuations than two weeks ago. P/E of 20.94x (down from 22.90x prior) and PEG of 2.28x (down from 2.48x) reflect a stock that has pulled back ~3.8% since my prior report, bringing it closer to — but not fully into — my prior entry zone of $220-$230. The Q1 FY2027 earnings beat (headline: 'ResMed (RMD) Beats Q1 Earnings and Revenue Estimates') is a genuine positive catalyst, with gross margin climbing as well ('RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs'). Core fundamentals remain elite: operating margin of 34.82% (vs. industry avg 14.01%), net margin of 27.79% (vs. industry avg 6.18%), ROE of 26.4% on near-zero leverage (D/E 0.07 vs. industry 0.54), and $2.85B in annual FCF. The primary concerns remain the forward growth lag (5-year EPS growth 9.2% vs. industry 12.76%) and a PEG of 2.28x that, while 46% cheaper than the industry average of 4.22x, still signals some absolute overvaluation. Analyst consensus target of $248.40 implies only 8.0% upside from current price. The earnings beat is incrementally positive for confidence in the thesis but doesn't fundamentally change the valuation math.
Key Strengths
- Unmatched profitability in the sector: operating margin 34.82% (2.5x industry avg 14.01%), net margin 27.79% (4.5x industry avg 6.18%), ROE 26.4% (3.4x industry avg 7.81%) — all achieved with near-zero leverage (D/E 0.07 vs. industry 0.54), confirming genuine economic moat
- Q1 FY2027 earnings and revenue beat with gross margin expansion ('RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs') validates the business durability thesis and suggests management may be tracking toward its 12-14% EPS growth target, which would bring PEG from 2.28x down toward 1.7x — approaching fair value territory
- Fortress balance sheet with $2.85B annual FCF, $1.01B cash, and D/E of 0.07 provides substantial margin of safety and strategic optionality; trading at a 45% P/E discount to industry average (20.94x vs. 38.10x) and 46% PEG discount (2.28x vs. 4.22x) despite being the sector's clear profitability leader
Key Concerns
- Structural growth lag vs. peers: forward 5-year EPS growth of 9.2% trails industry average of 12.76% by -28.0%, and revenue growth of 5.9% trails industry average of 12.64% by -53.3% — the business is a high-quality compounder but a below-average grower in its peer group, limiting multiple expansion potential
- Absolute valuation remains stretched: PEG of 2.28x is above 2.0x premium threshold; DCF intrinsic value estimate of $190-$215 (using management's higher 12% EPS guidance) to $190-$210 (using consensus 9.2%) places current price at 7-20% premium; analyst consensus target of $248.40 implies only 8.0% upside — insufficient risk/reward for initiating new large positions at current levels
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
ResMed's fundamentals are near-best-in-class. Profitability: gross margin 60.49% (vs. industry 44.32%, +36.5% premium), operating margin 34.82% (vs. industry 14.01%, +148.5% premium), net margin 27.79% (vs. industry 6.18%, +350% premium), ROE 26.4% (vs. industry 7.81%, +238% premium) — all achieved with D/E of only 0.07 vs. industry 0.54. Financial health: $1.01B cash, $2.85B annual FCF, near-zero debt. These are structural moat characteristics. Valuation concern: P/E of 20.94x is 45% below industry average of 38.10x (relative bargain), but PEG of 2.28x on 9.2% forward 5-year EPS growth means investors pay 2.28x the growth rate — elevated in absolute terms. DCF intrinsic value using $2.85B FCF, 9.2% growth for 5 years, 3% terminal, 9% discount rate yields fair value of approximately $190-$215/share, placing current price at a 7-20% premium to intrinsic value. Growth deceleration is the key concern: historical EPS growth of 23.2% YoY collapsing to 9.2% forward 5-year; revenue growth of only 5.9% vs. industry avg 12.64%. The Q1 FY2027 earnings beat (per recent headlines) is a positive data point that may support management's prior 12-14% EPS growth guidance target, which would push DCF fair value closer to $225-$235 and bring PEG down to ~1.7-1.9x at current price.
News Sentiment
ResMed just delivered a strong earnings surprise that quieted some of Wall Street's skeptics — at least temporarily. The medical device giant reported its first quarter fiscal 2027 results, beating both earnings and revenue estimates in what analysts are calling a confidence-building performance. Perhaps most encouraging: gross margins actually climbed, a sign that the company's profitable product mix is holding up well even as growth rates have moderated from pandemic-era highs. The earnings call, summarized in headlines like 'What ResMed Said on Its Q1 Earnings Call' and '3 Key Takeaways for Long-Term Investors,' offered long-term investors a reassuring picture of a business with multiple drivers intact. Management has been vocal about an unexpected tailwind from GLP-1 weight-loss drug users, who are increasingly seeking CPAP therapy as part of their sleep health journey — a dynamic that could push earnings growth toward the 12-14% range that leadership has targeted, well above the Wall Street consensus of around 9%. To be fair, not everyone was convinced heading into earnings. One pre-report analysis warned that RMD 'lacks the key combination of factors for an earnings beat' — but the company proved those doubts wrong. For everyday investors, the takeaway is straightforward: ResMed remains a highly profitable, nearly debt-free business generating nearly $3 billion in annual cash flow. The question isn't quality — it's whether the current price of roughly $230 already reflects most of that good news.
Risk Assessment
Primary risk: valuation compression if management fails to sustain the Q1 earnings momentum and forward growth remains anchored at 9.2% — at that growth rate, fair value is $190-$215, implying 7-17% downside from current price. Secondary risk: revenue growth at only 5.9% (vs. industry 12.64%) could accelerate the market's re-rating of RMD from 'premium compounder' to 'mature low-growth device company,' compressing P/E further from 20.94x toward 17-18x. Mitigation: stop loss at $208 (~8.9% below current price) sits just below the lower bound of the DCF range, limiting capital loss if thesis is wrong. The Q1 earnings beat reduces near-term earnings risk. The ultra-clean balance sheet (D/E 0.07, $2.85B FCF) provides substantial downside cushion. The Pomerantz legal investigation status remains an unresolved background risk. GLP-1 tailwind (management targeting 12-14% EPS growth citing GLP-1 patient CPAP compliance) is the primary upside catalyst — if realized, recalibrates fair value to $225-$240.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is RMD a halal stock?
Yes, ResMed Inc. (RMD) is halal-compliant per AAOIFI standards as of the latest quarterly review.
What is Plutrex's AI rating for RMD?
ResMed Inc. (RMD) has a Plutrex AI rating of 70.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is RMD a good investment?
According to Plutrex AI, RMD has a Buy rating (70.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in RMD?
US stocks like RMD can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in RMD?
Plutrex AI identifies the main risks for RMD by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.